AUCTA
PHARMACEUTICALS

Aucta Pharmaceuticals, Inc. (AUCTA, Latin-improved, enhanced) is a technology based company focusing on the development and commercialization of Branded Specialty Products.

Aucta is a pharmaceutical company creating better products of proven molecules using 505(b)(2) regulatory pathway. Through innovation, Aucta is creating new therapeutics, including new dosage forms, new dosing regimens and new indications.

Aucta has a clear therapeutic focus in CNS , Dermatology, and Pediatrics. We are committed to be patient centric by continuously bringing improved forms of proven molecules into the market place.

Aucta has operations in both New Jersey, U.S. and Shanghai, China.

VISION

Aucta aims to become a significant specialty pharma player in U.S. and China market place.

Since our founding, we have been focusing on building a company with sustainability:

- We have generated revenue every year with the goal to be at least operation cash neutral;
- We have carefully allocated capital to produce respectable investment return;
- We have grown the company organically and continuously to generate product ideas and IP internally;
- We have built a portfolio with clear therapeutic focus;
- We have built an energetic, dedicated and experienced team who share our vision.

Our vision is to become a fully integrated specialty pharma company, discovering, developing and commercializing our own products in both U.S. and China. We will continue to develop internal capability and technology that are platform based which can be extended to a series of products. We will build both internally and through collaborations with leading academic institutions, discovering capabilities to continue to generate ideas to drive long term growth of the company. We also plan to establish a specialized commercial team to support marketing of our products in U.S. in the areas of epilepsy and dermatology.

PIPELINE

We develop innovative treatments for certain indications and improve the performance of existing approved products, leveraging on our proprietary technology platforms. These enhanced products fulfill unmet medical needs, and they will be filed with FDA utilizing 505(b)(2) regulatory pathway.

Traditionally, the company derives its revenue from R&D services and on generic product milestones. Going forward, we envision majority of the our revenue will be coming from FDA and CFDA approved product sales (generic product revenue for the near term and branded product revenue for the mid/long term).

There are 3 programs undergoing Ph2/Ph3 clinical trials, one of which is an orphan drug product (FDA designated), two of which are innovative in nature as the only treatment available in the market place.

The company also has 10+ pipeline products at various stages of development.

MARKETED PRODUCTS